Positive Second Quarter Results
Second quarter sales were 1% higher than the prior year, driven by volume growth of 6%. Adjusted EBITDA of $207 million was 2% higher than the prior year, and adjusted earnings per share of $0.69 was $0.10 higher than the prior year.
Strong Growth in EMEA Region
EMEA showed the strongest growth driven by higher volume of herbicides, diamide partner sales, and branded Cyazypyr.
Successful Debt Management
Sale of $750 million subordinated notes due in 2055, leverage neutral, with proceeds used to redeem May 2026 senior notes and pay down commercial paper, improving metrics with rating agencies.
Promising Outlook for New Products
Strong demand for new actives, fluindapyr and Isoflex, with registrations and sales expected in new markets. Introduction of Dodhylex active with meaningful sales expected to begin in 2027.